Splenic Marginal Zone Lymphoma

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

  Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

  This clinical trial status update indicates an ongoing natural history study of Monoclonal B-Cell Lymphocytosis, chronic lymphocytic leukemi…

• CLINICAL_TRIALS research · 2026-04-08
  Clinical Trial Update: MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas [Phase 2]

  This clinical trial update summarizes the MALIBU Phase 2 study evaluating the combination of ibrutinib and rituximab in untreated marginal z…

• CLINICAL_TRIALS research · 2026-04-01
  Clinical Trial Update: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients [Phase 3]

  A Phase 3 trial is evaluating Rituximab plus Zanubrutinib versus Rituximab alone in untreated Splenic marginal zone lymphoma, with the study…

• CLINICAL_TRIALS research · 2026-03-23
  Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]

  Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-02-19
  Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]

  Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…

• CLINICAL_TRIALS research · 2026-01-20
  Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]

  Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…

• CLINICAL_TRIALS research · 2026-01-16
  Clinical Trial Update: Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

  Clinical trial to integrate molecular and clinical profiling of splenic marginal zone lymphoma (transformed form), currently recruiting.